Logo Volv Global
Contact
Recognising the patient trajectory

inAdvance – Finding patients earlier

Many patients show no signs a clinician would currently recognise, even as a disease develops. By the time symptoms appear or a diagnosis is confirmed, the disease may already be established and the window for changing its course narrower. This gap is wider for some conditions than others, particularly those that develop silently or fall outside routine screening.

inAdvance moves that point earlier. By surfacing who is likely to see their condition progress or need intervention sooner, it widens the window in which treatment can change the course of a disease.

Portrait of a man with curly hair and a patterned shirt, smiling slightly

Why early detection matters

A disease that develops silently still creates a burden on the patient and the healthcare system.

Diagnosis usually follows symptoms, which usually follow disease progression, so treatment often starts only once a disease is established and harder to change. Patients diagnosed early tend to have better outcomes, fewer complications and a higher quality of life; those diagnosed late carry a cost that rarely shows up as a missed diagnosis, because clinicians can only act on what they can see.

The human cost
of delay

Clinicians and health systems want to find every patient while treatment can still change a disease's course, wherever they enter care. inAdvance's approach has been shown to flag one rare neuroendocrine condition five to seven years earlier than usual diagnosis.

The uncredited value
of prevention

Market access and HTA teams want every avoided complication and year of stable health reflected in the price and funding a treatment secures. inAdvance predicts each patient's trajectory. One example, validated across more than 340,000 patients, gave a patient-level basis to credit the burden it avoids.

The evidence bar
for prognosis

Trial teams and regulators want predictive models that hold up under independent scrutiny before they change enrolment or submission decisions. inAdvance's model flags predicted clinical outcomes with accuracy to clinicians. This has been confirmed across two independent patient cohorts.

Where inAdvance creates value

Impact across the product lifecycle​

Clinical
Development

Detecting candidates earlier, before conventional treatment begins, so recruitment starts on a real population and de-risks the trial ahead.

Value, Access
& HEOR

Surfacing the early-stage population from real-world data, building an evidenced case for earlier diagnosis.

Medical
Affairs

Delivering an earlier, evidence-based signal that connects detection to the outcomes clinicians aim to improve.

Commercial
Excellence

Finding patients before conventional symptoms appear, helping plan where earlier intervention will matter most.

Portrait of an older man with a mustache, wearing a polo shirt, indoors

How inAdvance works

Detecting patients before symptoms appear

inAdvance applies Volv Global’s proprietary machine learning to population-scale real-world data, including electronic health records, claims data and other clinical sources, detecting subtle patterns that signal a disease developing before conventional symptoms appear.

Drawing on structured and unstructured records to build a fuller picture of a person’s health, it flags indicators that conventional diagnostics can miss, surfacing the signal while the decision stays with the clinician.

Talk to us

What people ask

Questions about earlier disease detection

A: inAdvance applies Volv Global's proprietary machine learning to population-scale real-world data, including biomarkers, electronic health records and other clinical data. It surfaces subtle patterns that signal a disease developing before conventional symptoms appear, so intervention can begin sooner.

A: Earlier detection gives clinicians and patients more time to act. Treatment started before a disease is established can change its course, and clinical trials that recruit from an earlier-stage population can test whether intervention works before symptoms take hold.

A: inAdvance supports clinical development teams estimating the scale of an early-stage population, HEOR and market access teams building the case for earlier diagnosis, medical affairs teams connecting earlier detection to outcomes, and commercial teams pinpointing where earlier intervention delivers the most value, often alongside inCare to find patients who are already eligible for treatment.

A: Accuracy depends on the disease and the data available. Our prognostic models are held to that same bar: one, validated across more than 340,000 patients, held up under independent clinician review across two separate patient cohorts.

A: Volv Global does not hold patient data. All work is conducted through trusted data partners operating under the privacy and regulatory frameworks that apply in each market. inAdvance surfaces and prioritises patients for clinical attention; it does not diagnose, prescribe, or replace clinical judgement.

Shaping the future today

Real-world impact​

Logo Volv Global

Your challenge

Our technology

Our solutions

Knowledge Hub

Meet Volv Global

Proprietary Machine Learning Methodology